Your browser doesn't support javascript.
loading
High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management.
Bradley, Courtney L; McMillin, Sara M; Hwang, Andrew Y; Sherrill, Christina H.
Afiliación
  • Bradley CL; Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA.
  • McMillin SM; Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA.
  • Hwang AY; Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA.
  • Sherrill CH; Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA.
Ann Pharmacother ; 56(8): 941-950, 2022 08.
Article en En | MEDLINE | ID: mdl-34706581
OBJECTIVE: To review the pharmacology, efficacy, and safety of high-dose once-weekly semaglutide for chronic weight management. DATA SOURCES: PubMed/MEDLINE and ClinicalTrials.gov were searched (inception to September 8, 2021) using keywords "semaglutide" and "obesity," "weight," "high dose," "high-dose," or "2.4." STUDY SELECTION AND DATA EXTRACTION: Clinical trials with published results were included. Publications studying the oral or <2.4 mg formulation of semaglutide were excluded. DATA SYNTHESIS: Four phase 3, multicenter, randomized, double-blind trials demonstrated efficacy of high-dose once-weekly semaglutide compared with placebo for weight loss. Study populations included patients with overweight or obesity (STEP 1, STEP 3, and STEP 4) or patients with diabetes and with overweight or obesity (STEP 2). Lifestyle interventions for diet and exercise were included for all participants. Weight loss from baseline was significant for all studies, and secondary outcomes demonstrated cardiometabolic improvements including waist circumference, systolic blood pressure, and lipid profiles. Gastrointestinal adverse effects were common, but the medication was otherwise well tolerated. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: High-dose semaglutide offers significant weight-lowering potential and favorable effects on cardiometabolic risk factors and glycemic indices. Clinicians and patients should consider the route and frequency of administration, adverse effect profile, and cost when choosing an antiobesity medication. The importance of concomitant lifestyle interventions should be emphasized. CONCLUSIONS: High-dose once-weekly semaglutide can significantly reduce weight, and although gastrointestinal adverse effects were common, it is generally well tolerated.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Péptidos Similares al Glucagón / Manejo de la Obesidad Tipo de estudio: Clinical_trials / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Ann Pharmacother Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Péptidos Similares al Glucagón / Manejo de la Obesidad Tipo de estudio: Clinical_trials / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Ann Pharmacother Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos